Canadian grants & funding programs

Canada Ontario Job Grant

Up to 50% funding for training, skills development, and workforce enhancement.

Ontario's workforce is our most valuable asset. As new technologies, globalization and shifting demographics rapidly change Ontario's economy, they alter the mix of available jobs and the skills people need to succeed in them. By building up education and training, we can maintain Ontario's competitive advantage, helping businesses and workers adapt to change and achieve their goals.

Ontario

Collaborative Industrial Research and Support to Innovative Entrepreneurship – Stream 1

50% funding for AI innovation, research, and collaboration projects.

Get a grant of up to $150,000 to cover up to 50% of eligible costs for carrying out research and an innovation project

Quebec

ICT Innovation Fund

up to 50% of innovation spend.

Encourages innovation in the ICT sector by providing funding for R&D and commercialization projects.

Canada

PARTENAR-IA – INNOVÉÉ – Industry

Cet appel de projets s’adresse ŕ l’ensemble des entreprises et coopératives québécoises, en priorité les PME et les start-ups, souhaitant réaliser un projet d’innovation pour le développement et la commercialisation de technologies en intelligence artificielle.

Quebec

PARTENAR-IA – MEDTEQ+ – Industry

The call for consortia innovation projects in artificial intelligence aims to support collaborative research projects and the development of healthcare technologies in Quebec. The program provides financial assistance to consortia of companies involved in collaborative research projects in artificial intelligence.

Quebec

PARTENAR-IA – CRITM – Industry

70% funding for R&D, AI projects, and greenhouse gas reduction initiatives.

The CRITM offers funding to companies and research centers for collaborative research projects in the metal transformation sector.

Quebec

Collaborate 2 Commercialize

50% funding for collaboration, commercialization, and industry-driven projects.

This program supports the collaboration between Academia and Industry to solve an industry-based problem and drive the commercialization of Intellectual Property [IP]. The institution will leverage the unique skills and specialized infrastructure that is instrumental to streamline internal innovations and commercialization needs. Resulting in targeted training of individuals and direct engagement with Industry to work on commercially viable solutions.

Ontario

CABHI Ignite Program

Up to 150% funding for R&D, prototyping, testing, and validation of innovations.

The CABHI Ignite Program offers early-stage Canadian innovators funding between $50,000 to $150,000 CAD, along with acceleration services, to develop, test, and validate solutions aimed at improving the lives of older adults and those affected by dementia.

Canada

Canada-Alberta Job Grant

75% funding for employee training, skills development, and essential workplace education.

The Canada-Alberta Job Grant provides funding for employers to help employees and unemployed Albertans access training opportunities. Employers decide who gets training and what type of training may be needed for their employees.

Alberta

SMART FY 2023 Fellowship Program: Sex Offender Registry Law Enforcement Liaison and Sexual Violence Prevention Fellowships

OJP is committed to advancing work that promotes civil rights and racial equity, increases access to justice, supports crime victims and individuals impacted by the justice system, strengthens community safety, protects the public from crime and evolving threats, and builds trust between law enforcement and the community. Awards made under the SMART Fellowship Program will fund fellowships for a period of 12 months. The fellows will work closely with SMART Office staff and will work onsite periodically in the SMART Office in Washington, D.C.. . The purpose of these fellowships is to provide guidance to jurisdictions on how to either obtain or maintain substantial implementation of SORNA and improve management of those convicted of sexual offenses through research and practice, with the aim of reducing sexual violence. Fellows will collaborate with the SMART Office and DOJ staff to provide critical outreach, data, research, and subject matter expertise to inform the development of new strategies and programs for practitioners in the field as well as assist the SMART Office in its mission.

United States

Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) will support transformative research to identify and validate mechanisms, signaling pathways, and therapeutic targets, for understanding and reversing the effects of an overdose and the observed toxicities caused by acute Ultra-Potent Synthetic (UPS) opioid exposure. This FOA will also support mechanistic studies of persistent or delayed pathophysiological effects after acute exposure to UPS opioids.

United States

OCI - Critical Industrial Technologies Initiative

75% funding for advanced tech in mining, manufacturing, agri-food, and construction.

Driving the commercialization and adoption of critical technologies to advance Ontario’s mining, advanced manufacturing, construction, and agri-food sectors.

Ontario

Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required)

The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies involving humans that expand our knowledge of theinterrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythm and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.

United States

Rural Economic Development program – Economic Diversification and Competitiveness Stream

50% funding for community projects, business growth, and infrastructure development.

The RED program provides cost-share funding to support activities that create strong rural communities in Ontario. It aims to help address barriers to economic development and labour force challenges, better position rural communities to attract or retain investment, enhance economic growth, and strengthen community capacity and support for economic development.

Ontario

Development of the Fetal Immune System (R01 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the development of the fetal immune system.

United States

OCI - Technology Demonstration Program1

50% funding for digital adoption, training, and technology upgrades for Ontario SMEs.

The Technology Demonstration Program is designed to assist Ontario-based SMEs, particularly those with a completed DMAP project, in implementing the digital technologies outlined in their DMAP. It targets SMEs looking to drive growth through digital innovation, with eligibility criteria including a minimum annual revenue threshold.

Ontario

OCI - Technology Demonstration Program

50% funding for digital adoption plans, technology upgrades, and training for SMEs.

A government-funded program that provides funding to businesses in Ontario to support the development and adoption of advanced technologies.

Ontario

OCI - Technology Demonstration Program3

50% funding for digital adoption, training, and technology upgrades for Ontario SMEs.

The Technology Demonstration Program is designed to assist Ontario-based SMEs, particularly those with a completed DMAP project, in implementing the digital technologies outlined in their DMAP. It targets SMEs looking to drive growth through digital innovation, with eligibility criteria including a minimum annual revenue threshold.

Ontario

OCI Collaborate 2 Commercialize (C2C)

50% funding for collaboration, R&D, and commercialization of innovative solutions.

A funding program that provides financial assistance to small and medium-sized enterprises (SMEs) in Ontario to help them adopt and implement innovative technologies or processes that will increase productivity and competitiveness.

Ontario

Waste Heat Recovery – Stream 1: Feasibility study

75% funding for infrastructure, design, and construction of thermal energy systems.

The Soutien ŕ l’implantation d’infrastructures program offers financial assistance for the design, construction, and commissioning of eligible infrastructures related to the capture and distribution of thermal waste.

Quebec

Ontario Centre of Innovation – Voucher for Innovation and Productivity (VIP) – Industry-Academic

Up to $150,000 non-repayable contribution to cover a portion of R&D collaboration costs.

Supports Ontario companies collaborating with publicly funded research institutions to develop, validate, or de-risk new products and processes, including cybersecurity and privacy solutions.

Ontario

Ontario Automotive Modernization Program (O-AMP)

50% funding for advanced technology, process efficiency, and product development in automotive.

The Ontario Automotive Modernization Program (O-AMP) is an Ontario government funding program that supports Ontario automotive parts manufacturers as they invest in new hardware/software technologies and lean methodology to improve their operational efficiency and competitiveness.

Ontario

Yukon Business Innovation Program

Non-repayable contributions covering a portion of R&D and commercialization costs.

Funds applied research, technology development, and commercialization activities, including software security, privacy, and identity solutions.

Yukon

Digitalization Competence Centre – Technology Demonstration Program (DCC-TDP)

Up to 50% of eligible costs to a maximum of $150,000 for technology demonstration and adoption.

Supports Ontario SMEs to implement and demonstrate digital technologies (e.g., Industry 4.0, automation, robotics, data/AI for manufacturing) that improve productivity and competitiveness.

Ontario

OCI Voucher for Innovation and Productivity (VIP)

Up to $150,000 non-repayable to the academic partner; typically 1:1 cash/in-kind contributions from the SME apply (varies by stream).

Funds Ontario SMEs to collaborate with accredited colleges/universities/research hospitals on industry-driven innovation, product/process development, and technology adoption projects that improve productivity and competitiveness.

Ontario

NSERC Applied Research and Development (ARD) Grants – Colleges

NSERC typically covers the majority of project costs through the college, up to $150,000 per year.

Funds collaborative projects with Canadian colleges/CEGEPs to solve applied research and innovation challenges such as process optimization, prototyping, and technology adoption for SMEs.

Canada

Ontario Centre of Innovation – Voucher for Innovation and Productivity (VIP)

Non-repayable contribution; typical support up to $150,000 depending on stream and matching requirements.

Supports industry–academic collaborations to develop, validate, and commercialize innovative technologies. Funding covers research performed by Ontario academic institutions for company-driven projects.

Ontario

PARTENAR-IA – PRIMA – Industry

The PRIMA Advanced Materials Research and Innovation Hub is offering a non-refundable grant up to $150,000 per partner company (to a maximum of $600,000) to cover up to 50% of the expenses when partnering with at least one other business and a research centre on an artificial intelligence project in the field of advanced materials.

Quebec

Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, or treatment of cancer, rehabilitation from cancer, or the continuing care of cancer patients and the families of cancer patients.

United States

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed)

United States

Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical Trial Not Allowed)

This concept proposes to advance methodological rigor in NIDA-relevant research by supporting training on the responsible analyses of complex, large-scale datasets involving brain, behavioral, genomic, and socioenvironmental data through: . 1. Courses for Skills Development. 2. Curriculum or Methods Development

United States

Innovation in Quantum Technologies – Stream 1

50% funding for AI and quantum tech projects, R&D, and collaboration opportunities.

Funding contributes up to $150,000, covering 50% of eligible expenses for innovation projects related to the development and growth of products or services originating the startup.

Quebec

Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies that expand our knowledge of theinterrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythm and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.

United States

PARTENAR-IA – CQDM – Industry

35% funding for AI-driven biopharma R&D, covering project costs and research expenses.

CQDM is launching a new program to fund activities carried out in companies that are part of collaborative R & D projects in artificial intelligence applicable to the biopharmaceutical sector.

Quebec

Product Demonstration Program - Alberta Innovates

75% funding for product pilots, demonstrations, and strategic partnerships to boost your market presence.

The Product Demonstration Program provides up to $150,000 to Alberta tech companies intending to commercialize their products and achieve optimal market position.

Alberta

Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics)and (2) medical therapeutic and diagnostic devices, including software as a medical device. This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.

United States

BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional)

Reissue of RFA-MH-19-400. This funding opportunity announcement (FOA), in support of the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, is one of several FOAs aimed at supporting transformative discoveries that will lead to breakthroughs in understanding human brain function. Guided by the long-term scientific plan, BRAIN 2025: A Scientific Vision, this FOA specifically seeks to support efforts addressing core ethical issues associated with research focused on the human brain and resulting from emerging technologies and advancements supported by the BRAIN Initiative. The hope is that efforts supported under this FOA might be both complementary and integrative with the transformative, breakthrough neuroscience discoveries supported through the BRAIN Initiative.

United States

Innovation in Quantum Technologies – Stream 2

50% funding for AI and quantum tech projects, R&D, and collaboration opportunities.

Funding for quantum technology projects to cover up to 30% of eligible expenses (50% for technology showcase), with a maximum of $150,000.

Quebec

Rural Economic Development Fund (RED)

50% funding for business growth, community projects, and workforce development in rural Ontario.

The Rural Economic Development Fund (RED), by the Ministry of Agriculture, Food, and Rural Affairs (OMAFRA), supports regional economic development activities in rural southern Ontario communities. The program currently focuses on non-profits, organizations and associations, and municipal governments, and provides them with additional resources to carry out projects that boost regional economic opportunities.

Ontario

Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)

The purpose of the Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools is to stimulate basic and clinical research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. REAP grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. REAP grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students at health professional schools or graduate schools to meritorious research projects, and to strengthen the research environment of the applicant institution. Eligible institutions must award NIH-relevant baccalaureate or advanced degrees in health professions and have received less than $6 million per year of NIH support (total costs) in 4 of the last 7 fiscal years. In this FOA, a college is a stand-alone entity and not a component of a university system.

United States

Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined populations experiencing health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.

United States

Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (UT1/UT2) Clinical Trial Not Allowed

This FOA provides support using the STTR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.

United States

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined population groups who experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.

United States

Interactive Digital Media (IDM) Biomedical Science Resources for Pre-College Students and Teachers (SBIR) (R43/R44 Clinical Trial Not Allowed)

The purpose of this Notice of Funding Opportunity (NOFO) is to provide opportunities for eligible small business concerns (SBCs) to develop interactive digital media (IDM) biomedical science resources for pre-college students and teachers.

United States

Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)

The FOA intends to spur the development of cost-effective technologies that may reduce or even eliminate disparities in SUD treatment. Disparities due to geographical access or rural/urban divide, due to treatment cost, or due to stigma will be specifically targeted. The intention is to bring to the treatment to the patient, not the patient to the treatment.

United States

Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R41/R42 Clinical Trial Optional)

The FOA intends to spur the development of cost-effective technologies that may reduce or even eliminate disparities in SUD treatment. Disparities due to geographical access or rural/urban divide, due to treatment cost, or due to stigma will be specifically targeted. The intention is to bring to the treatment to the patient, not the patient to the treatment.

United States

Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed)

This Notice of Funding Opportunity (NOFO) supports Phase I (R43), Phase II (R44), Direct to Phase II (R44), and Fast Track (R44) Small Business Innovative Research (SBIR) grant applications from small businesses concerns (SBCs) to develop resources, new methods, and approaches that can be applied in testing strategies to help understand the role of environmental chemicals in the etiology of the neurodevelopmental disorders. There is a need for novel and innovative approaches including New Approach Methodologies (NAMs) that can provide effective ways to address current challenges and gaps in the assessment of Developmental Neurotoxicity (DNT). These screening systems or technologies, when fully developed and validated with appropriate throughput and controls, are expected to provide cost-effective, quicker and/or comprehensive results to understand the underlying role of environmental chemicals in the DNT.

United States

Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)

This FOA provides support using the SBIR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.

United States